Harmony Biosciences is trading 4.05% down at $39.59 on September 28, 2026; broader market risk-off pressure is the clearest available context, though no direct link was reported.
- U.S. stocks fell as oil rose amid stalled U.S.-Iran talks and Treasury yields climbed, renewing inflation and rate concerns.
- No clear company-specific announcement explaining the drop surfaced. The latest company news provided was a September 22 World Narcolepsy Day release; September 25 patent-defense news was earlier and bullish, so it does not explain today’s decline.